RESUMEN
Bronchial asthma (BA) is a chronic respiratory disease closely related to immune system dysregulation. Traditional Chinese medicine has long adopted the strategy of Sanao decoction in the treatment of bronchial asthma. However, due to the multi-target and multi-pathway characteristics of Chinese herbal medicine, we are still unclear about the specific mechanism of Sanao decoction in treating bronchial asthma. To investigate the mechanism of action of Sanao decoction in the treatment of BA using a network pharmacology approach and preliminary validation by molecular docking technology. Traditional Chinese medicine systems pharmacology database and analysis platform and UniProt databases were used to search the active ingredients and targets of Sanao decoction, and BA-related targets were screened according to GeneCards and online Mendelian inheritance in man database databases. The intersection targets were imported into the STRING database to construct a protein-protein interaction network, and Cytoscape 3.9.1 software was used to screen out hub genes. This study also constructed a "drug-ingredient-target" visual network diagram. Gene Ontology and Kyoto Encyclopedia of Genomes enrichment analysis was performed on targets in the protein-protein interaction network using the ClusterProfiler package in R, with a P valueâ <â .05. Autodock software was used for molecular docking to complete the preliminary verification of core components and targets. A total of 73 active compounds and 308 targets of Sanao decoction, including 1640 BA-related disease targets, were retrieved from mainstream databases. Gene Ontology analysis and Kyoto encyclopedia of genes and genomes enrichment analysis suggested that Sanao decoction plays a role in the treatment of BA through signaling pathways such as PI3K-Akt, MAPK, and IL-17 signaling pathway. The 9 core goals represent the main elements related to Sanao decoction in the treatment of BA. Subsequently, the molecular docking results showed that most of the active compounds of Sanao decoction have strong binding efficiency with the hub gene. Sanao decoction has a key impact on BA through multiple channels. In summary, this intricate network reflects the potential of Sanao decoction in treating BA, a multifactorial disease. In addition, this study laid the foundation for further in vivo and in vitro experimental research and expanded the clinical application of Sanao decoction.
Asunto(s)
Asma , Enfermedades Bronquiales , Medicamentos Herbarios Chinos , Humanos , Simulación del Acoplamiento Molecular , Farmacología en Red , Fosfatidilinositol 3-Quinasas , Asma/tratamiento farmacológico , Asma/genética , Bases de Datos Genéticas , Medicina Tradicional China , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéuticoRESUMEN
BACKGROUND AND AIMS: Post-tuberculosis bronchial stenosis (PTBS) is one of the most common complications of tracheobronchial tuberculosis. Silicone stent serves as a major treatment for maintaining airway patency. However, silicone stent placement remains a large challenge in patients with severe cicatricial PTBS. Our objective was to evaluate the efficacy and safety of covered, self-expanding, metallic stents (SEMSs) as a transition to silicone stent implantation for treating severe PTBS. METHODS: We retrospectively reviewed the data of patients with severe PTBS who received airway stenting in the First Affiliated Hospital of Guangdong Medical University between September 2015 and May 2019. The types of the stent, intervention procedures, bronchoscopic findings, clinical outcomes and related complications were collected and analyzed. RESULTS: Fifty-eight cases with severe PTBS were included in this study. Thirteen (22.4%) of the patients received bronchial silicone stent implantation immediately after dilations. For the remaining 45 (77.6%) patients, silicone stents could not be deployed after dilations and SEMSs implantation was implemented as a bridge to silicone stenting. The SEMSs were placed for an interval of 28.4 ± 11.1 days. All of the silicone stents were inserted successfully following the removal of SEMSs. No SEMS-related complication occurred. The subgroup analysis showed that patients who received transitional SEMSs had less luminal caliber but fewer transbronchial dilations before silicone stent implantation (p < 0.05). CONCLUSION: Covered SEMS placement as a transition to silicone stenting could serve as a feasible procedure to reduce complications and improve the success rate of silicone stent implantation in patients with severe PTBS.The reviews of this paper are available via the supplemental material section.
Asunto(s)
Enfermedades Bronquiales , Stents Metálicos Autoexpandibles , Tuberculosis , Enfermedades Bronquiales/etiología , Enfermedades Bronquiales/cirugía , Constricción Patológica/etiología , Constricción Patológica/cirugía , Humanos , Gravedad del Paciente , Estudios Retrospectivos , Stents Metálicos Autoexpandibles/efectos adversos , Siliconas , Stents , Resultado del Tratamiento , Tuberculosis/complicacionesRESUMEN
OBJETIVO: Determinar predictores de buena respuesta con el uso de prótesis en la estenosis traqueobronquial. MATERIALES Y MÉTODO: Estudio retrospectivo descriptivo de una serie de casos entre junio de 2014 y junio de 2016. Se revisaron registros clínicos, protocolos operatorios, estudios histopatológicos y de imagen. Se consignaron antecedentes demográficos y clínicos al ingreso y luego del procedimiento, etiología de la estenosis traqueal, necesidad de oxígeno en litros, estadía hospitalaria, morbilidad asociada al procedimiento, indicación de terapia complementaria posterior y sobrevida. Se analizaron los datos con estadística descriptiva y analítica. RESULTADOS: Se realizaron 68 procedimientos, en 44 pacientes, 24 mujeres, el diagnóstico principal fue estenosis traqueal con 40 casos. La etiología neoplásica fue el 88% de los casos. El Performance status (PS) de ingreso fue mayor o igual a 2 en el 68% y posterior al procedimiento disminuyó a 22% p < 0,05. En 36 casos los pacientes requerían al menos 1 L de oxígeno lo que disminuyó en 13 casos posterior a la intervención p < 0,05. El tiempo de hospitalización promedio fue 6,2 días (1-60). En 13 pacientes con patología neoplásica se indicó terapia paliativa complementaria. La morbilidad asociada al procedimiento fue de 2,9% dado por prótesis desplazada y lesión iatrogénica. La sobrevida fue de 27% a un año. CONCLUSIONES: La etiología benigna, el PS previo a la intervención menor o igual a 3, requerimiento de oxígeno de 1 litro y obstrucción tumoral menor al 70% del lumen fueron elementos de buena respuesta.
AIM: Determine good response predictors in use of stent in benign and malignant tracheobronchial stenosis. MATERIAL AND METHODS: We retrospectively reviewed medical records of patients submitted to the procedure in the period 2014 to 2016. Clinical records, operative protocols, and histopathological and imaging studies were reviewed. Demographic and clinical data, performance status (PS) at admission and after the procedure, etiology of tracheal stenosis, need for oxygen in liters (L) Post-intervention, hospital stay, procedure-related morbidity, indication of therapy (Chemotherapy and/or Radiotherapy) and survival. Data were analyzed with descriptive and analytics statistics. RESULTS: A total of 68 procedures were performed in 44 patients, 24 women. Tracheal stenosis 40 cases were diagnosed. The malignant etiology was 88%. The admission PS was greater than or equal to 2 in 68% and 22% after the procedure. The oxygen requirements prior to the procedure were at least 1 L in 36 cases and decreased in 13 cases after the procedure. The average hospitalization period was 6.2 days (1-60). Complementary therapy was indicated in 13 patients; the morbidity associated with the procedure was 2.9%, displaced installation and iatrogenic injury. The one year survival was 27%. CONCLUSIONS: Benign etiology, el PS minor than or equal to 3, oxygen requirements prior to the procedure of 1 L and tumoral obstruction less than 75% were good response predictors in our study.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Estenosis Traqueal/cirugía , Enfermedades Bronquiales/cirugía , Stents , Prótesis e Implantes , Estenosis Traqueal/complicaciones , Enfermedades Bronquiales/complicaciones , Análisis de Supervivencia , Estudios Retrospectivos , Resultado del Tratamiento , Obstrucción de las Vías Aéreas/etiología , Tiempo de InternaciónRESUMEN
An asymptomatic 48-year-old man presented with multiple aneurysms in a primary racemose hemangioma of the right bronchial artery. Bronchial arteriography revealed a tortuous artery with four fusiform aneurysms of varying sizes and aneurysmal dilatation with marked thrombus formation in the long segment of the distal portion. Because the tip of catheter could not pass beyond the aneurysmal dilatation, we performed balloon-occluded embolization using a mixture of N-butyl-2-cyanoacrylate (NBCA) and iodized oil. For four other aneurysms, we performed embolization using a coil alone or with NBCA. After 6 months, right bronchial arteriography revealed no enhancement of the aneurysms. Despite the rarity of this procedure, embolization with NBCA is a good option for bronchial artery aneurysm embolization.
Asunto(s)
Aneurisma/terapia , Enfermedades Bronquiales/terapia , Embolización Terapéutica/métodos , Enbucrilato/uso terapéutico , Hemangioma/terapia , Aneurisma/complicaciones , Aneurisma/diagnóstico por imagen , Arterias Bronquiales/diagnóstico por imagen , Enfermedades Bronquiales/complicaciones , Enfermedades Bronquiales/diagnóstico por imagen , Angiografía por Tomografía Computarizada/métodos , Diagnóstico Diferencial , Hemangioma/complicaciones , Hemangioma/diagnóstico por imagen , Humanos , Aceite Yodado/uso terapéutico , Masculino , Persona de Mediana EdadRESUMEN
PURPOSE: This report details our preliminary results of ventilation catheter-assisted airway stenting under local anaesthesia for airway stenosis. MATERIALS AND METHODS: Fifteen consecutive patients with airway stenosis underwent ventilation catheter-assisted airway stenting under local anaesthesia. A 4F angiographic catheter was used as the ventilation catheter. During the treatment, the distal tip of the ventilation catheter was placed across the stenosis into one of the main bronchi and the proximal tip of the catheter was linked to the oxygen tube for oxygen supplementation. Airway stenting was performed under ventilation support. Patients maintained autonomous respiration throughout the procedures. Data on technical success, clinical outcome and follow-up were collected and analysed. RESULTS: Ventilation catheter-assisted airway stenting under local anaesthesia was technically successful and well tolerated in all patients. Respiratory difficulty was improved in all patients after treatment. The average Hugh-Jones classification grade, arterial oxygen saturation value, and respiratory rate improved from 4.20 ± 0.68, 80.60 ± 3.83%, and 30.33 ± 2.02 times/min, respectively, before stenting to 1.47 ± 0.52 (P < 0.001), 94.93 ± 1.33% (P < 0.001), and 18.07 ± 1.33 times/min (P < 0.001), respectively, after stenting. After 2-11 months (average 5.73 ± 2.40 months) of follow-up, one patient experienced re-stenosis of the stent. The mean survival time of the 15 patients was 162.00 ± 71.60 days (range 55-320 days). CONCLUSIONS: Ventilation catheter-assisted airway stenting under local anaesthesia can be an effective, simple and safe method for airway stenosis.
Asunto(s)
Obstrucción de las Vías Aéreas/terapia , Anestesia Local , Enfermedades Bronquiales/terapia , Catéteres , Respiración Artificial/instrumentación , Stents , Estenosis Traqueal/terapia , Adulto , Anciano , Anciano de 80 o más Años , Obstrucción de las Vías Aéreas/diagnóstico por imagen , Constricción Patológica/terapia , Femenino , Humanos , Imagenología Tridimensional , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
INTRODUCTION: Respiratory illness, often associated with cough and sputum, is frequent. In Brazil, herbal medicines are often recommended as a first-line treatment for respiratory illness. There exists uncertainty regarding the effectiveness of these treatments. No systematic review has evaluated Brazilian medicinal plants (BMP) to treat upper respiratory tract and bronchial illness (URTI). METHODS AND ANALYSIS: We will conduct a systematic review and, if appropriate, a series of meta-analyses evaluating the safety and effectiveness of BMP for URTI. Eligible randomised controlled trials and observational studies will enrol adult or paediatric patients presenting with URTI treated by BMP approved by the Brazilian Health Surveillance Agency compared with placebo, no treatment or an alternative therapy. Our search will include the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Illness Group's Specialized Register; MEDLINE; EMBASE; CINAHL (Cumulative Index to Nursing and Allied Health Literature); Web of Science; AMED; LILACS; CAB abstracts; clinical trial.gov; the WHO Trial Register and the Brazilian thesis database (CAPES) without any language restrictions. Outcomes of interest are time to resolution of clinical symptoms and/or signs (cough, sputum production or activity limitations), severity of symptoms prior to resolution and major/minor adverse events. Teams of reviewers will, independently and in duplicate, screen titles and abstracts and the complete full text to determine eligibility. For eligible studies, reviewers will perform data abstraction and assess risk of bias of eligible trials. When appropriate, we will conduct meta-analyses. We will also assess the quality of body of evidence (confidence in estimates of effect) for each of the outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. ETHICS AND DISSEMINATION: The systematic review will be published in a peer-reviewed journal. Brief reports of review findings will be disseminated directly to appropriate audiences via email and other modes of communication. The review will guide healthcare practice and policy in Brazil. TRIAL REGISTRATION NUMBER: Prospero CRD42014007057.
Asunto(s)
Fitoterapia , Plantas Medicinales , Enfermedades Respiratorias/tratamiento farmacológico , Brasil , Enfermedades Bronquiales/tratamiento farmacológico , Humanos , Metaanálisis como Asunto , Estudios Observacionales como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Proyectos de Investigación , Revisiones Sistemáticas como AsuntoRESUMEN
PURPOSE: We aimed to report our preliminary results of subcarinal ventilation-assisted Y-shaped stent insertion under local anesthesia for patients with complex lower tracheal-carinal-main bronchial complex stenosis. MATERIALS AND METHODS: Seven consecutive patients with lower tracheal-carinal-main bronchial complex stenosis underwent Y-shaped stent insertion under local anesthesia. During the procedure, subcarinal ventilation was performed using a 4 F angiographic catheter, and stent insertion was performed under the protection of ventilation. Data on technical success, clinical outcome, and follow-up were collected and analyzed. RESULTS: Subcarinal ventilation-assisted Y-shaped stent insertion under local anesthesia was technically successful in all patients without any major procedure-related complications. Seven stents were inserted in seven patients. Respiratory function improved in all patients, with the Hugh-Jones classification of respiratory status improving from grade IV-V before stenting to grade I-II after stenting. During the follow-up, one patient experienced re-stenosis of the stent. Average survival time was 185.7 days (range, 96-285 days) after the stenting procedure. CONCLUSION: Subcarinal ventilation-assisted Y-shaped stent insertion under local anesthesia can be an effective, simple, and safe method for lower tracheal-carinal-main bronchial complex stenosis.
Asunto(s)
Anestesia Local , Enfermedades Bronquiales/cirugía , Respiración Artificial/métodos , Stents , Estenosis Traqueal/cirugía , Anciano , Obstrucción de las Vías Aéreas/diagnóstico por imagen , Obstrucción de las Vías Aéreas/cirugía , Enfermedades Bronquiales/diagnóstico por imagen , Constricción Patológica/diagnóstico por imagen , Constricción Patológica/cirugía , Diseño de Equipo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tomografía Computarizada Multidetector , Estenosis Traqueal/diagnóstico por imagen , Resultado del TratamientoRESUMEN
INTRODUCTION: Tracheobronchoscopy allows endoscopic inspection and management of the tracheobronchial system. MATERIAL: The recommendation was developed in 1997 and updated in 2004 and 2009. RESULTS: The recommendations comment on indications and contra-indications, instruments, anesthesia and complications of endoscopic tracheobronchoscopy. DISCUSSION: Rapid technical advances in endoscopy have led to changes in indications for different procedures, especially as pertains to rigid and flexible endoscopy. The recommendations are designed to provide guidance for ENT and affiliated specialties for choosing and processing instruments and sedation methods.
Asunto(s)
Enfermedades Bronquiales/diagnóstico , Enfermedades Bronquiales/terapia , Broncoscopía/normas , Enfermedades de la Tráquea/diagnóstico , Enfermedades de la Tráquea/terapia , Adulto , Anestesia General , Anestesia Local , Broncoscopios , Broncoscopía/efectos adversos , Niño , Sedación Consciente , Contraindicaciones , Diseño de Equipo , Alemania , Humanos , Bloqueo NerviosoRESUMEN
Introducción. El síndrome bronquial obstructivo en niños puede acompañarse de diversos grados de hipoxemia. La saturación arterial de oxígeno (SaO2) es el mejor medio para valorarhipoxemia, pero suele inferirse por una escala para valorar dificultad respiratoria, aún no validada.El objetivo fue validar la escala de dificultad respiratoria utilizada en la Argentina y compararla con la utilizada en Chile.Población, material y métodos. Se incluyeron 200 niños menores de 2 años con síndrome bronquial obstructivo y se registraron SaO2 y componentesde ambas escalas (frecuencia respiratoria, frecuencia cardíaca, tiraje, sibilancias, cianosis).Se evaluó la capacidad de los componentes para predecir hipoxemia (SaO2 ≤95 y SaO2 ≤91) por regresiónlogística. Se estimó la correlación entre la escala argentina y la SaO2. Se determinó el mejor punto de ambas escalas para predecir hipoxemia(curvas ROC). Se calculó sensibilidad, especificidad, valores predictivos y razones de verosimilitud de ambas escalas para predecir hipoxemia.Resultados. Sólo el tiraje fue predictor independiente de hipoxemia (SaO2 ≤95 y ≤91) (OR: 3,1 IC95 por ciento:1,6-5,9 y OR: 13,8 IC95 por ciento:1,8-105,4, respectivamente).La escala argentina mostró aceptablecorrelación con la SaO2 (Spearman: -0,492; p< 0,0001) en SaO2 ≤91, la escala argentina mostró la mejor capacidad diagnóstica (abc= 0,904).Un puntaje ≥5 fue el mejor punto para predecir hipoxemia (sensibilidad= 100 por ciento, especificidad= 54,3 por ciento). La escala chilena mostró una sensibilidadsensiblemente inferior.Conclusión. La escala argentina fue suficientemente sensible para predecir hipoxemia (SaO2 ≤91) en un puntaje ≥5, pero no mostró especificidadque permita una correcta discriminaciónpor encima de este punto. Esta escala sólo permite identificar niños que no se beneficiarían con el uso de O2.
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Pruebas Respiratorias , Enfermedades Bronquiales , Diagnóstico Clínico , Consentimiento Informado , Valor Predictivo de las Pruebas , Enfermedad Pulmonar Obstructiva Crónica , Índice de Severidad de la EnfermedadRESUMEN
Introducción. El síndrome bronquial obstructivo en niños puede acompañarse de diversos grados de hipoxemia. La saturación arterial de oxígeno (SaO2) es el mejor medio para valorarhipoxemia, pero suele inferirse por una escala para valorar dificultad respiratoria, aún no validada.El objetivo fue validar la escala de dificultad respiratoria utilizada en la Argentina y compararla con la utilizada en Chile.Población, material y métodos. Se incluyeron 200 niños menores de 2 años con síndrome bronquial obstructivo y se registraron SaO2 y componentesde ambas escalas (frecuencia respiratoria, frecuencia cardíaca, tiraje, sibilancias, cianosis).Se evaluó la capacidad de los componentes para predecir hipoxemia (SaO2 ≤95 y SaO2 ≤91) por regresiónlogística. Se estimó la correlación entre la escala argentina y la SaO2. Se determinó el mejor punto de ambas escalas para predecir hipoxemia(curvas ROC). Se calculó sensibilidad, especificidad, valores predictivos y razones de verosimilitud de ambas escalas para predecir hipoxemia.Resultados. Sólo el tiraje fue predictor independiente de hipoxemia (SaO2 ≤95 y ≤91) (OR: 3,1 IC95 por ciento:1,6-5,9 y OR: 13,8 IC95 por ciento:1,8-105,4, respectivamente).La escala argentina mostró aceptablecorrelación con la SaO2 (Spearman: -0,492; p< 0,0001) en SaO2 ≤91, la escala argentina mostró la mejor capacidad diagnóstica (abc= 0,904).Un puntaje ≥5 fue el mejor punto para predecir hipoxemia (sensibilidad= 100 por ciento, especificidad= 54,3 por ciento). La escala chilena mostró una sensibilidadsensiblemente inferior.Conclusión. La escala argentina fue suficientemente sensible para predecir hipoxemia (SaO2 ≤91) en un puntaje ≥5, pero no mostró especificidadque permita una correcta discriminaciónpor encima de este punto. Esta escala sólo permite identificar niños que no se beneficiarían con el uso de O2.(AU)
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Enfermedades Bronquiales , Enfermedad Pulmonar Obstructiva Crónica , Diagnóstico Clínico/estadística & datos numéricos , Pruebas Respiratorias , Consentimiento Informado , Valor Predictivo de las Pruebas , Índice de Severidad de la EnfermedadRESUMEN
PURPOSE: To assess the effectiveness of airway stenting performed exclusively under radiological guidance for the palliation of malignant tracheobronchial strictures. METHODS: We report our experience in 16 patients with malignant tracheobronchial stricture treated by insertion of 20 Ultraflex self-expandable metal stents performed under fluoroscopic guidance only. Three patients presented dysphagia grade IV due to esophageal malignant infiltration; they therefore underwent combined airway and esophageal stenting. All the procedures were performed under conscious sedation in the radiological room; average procedure time was around 10 min, but the airway impediment never lasted more than 40 sec. RESULTS: We obtained an overall technical success in 16 cases (100%) and clinical success in 14 patients (88%). All prostheses were successfully placed without procedural complications. Rapid clinical improvement with symptom relief and normalization of respiratory function was obtained in 14 cases. Two patients died within 48 hr from causes unrelated to stent placement. Two cases (13%) of migration were observed; they were successfully treated with another stent. Tumor overgrowth developed in other 2 patients (13%); however, no further treatment was possible because of extensive laryngeal infiltration. CONCLUSIONS: Tracheobronchial recanalization with self-expandable metal stents is a safe and effective palliative treatment for malignant strictures. Airway stenting performed exclusively under fluoroscopic view was rapid and well tolerated.
Asunto(s)
Anestesia Local/métodos , Enfermedades Bronquiales/cirugía , Cuidados Paliativos/métodos , Stents , Tráquea/diagnóstico por imagen , Estenosis Traqueal/cirugía , Anciano , Anciano de 80 o más Años , Sedación Consciente/métodos , Esófago/diagnóstico por imagen , Esófago/cirugía , Femenino , Humanos , Imagenología Tridimensional/métodos , Masculino , Persona de Mediana Edad , Stents/efectos adversos , Tomografía Computarizada por Rayos X/métodos , Resultado del TratamientoRESUMEN
DNA vaccination is discussed as having the potential of improving therapy of type I allergies. A mouse model was used to investigate the effect of DNA vaccination against sensitisation with the clinically relevant Phl p 5b major allergen from timothy grass pollen in an immunoprophylactic experimental setup. Pre-treating the mice with Phl p 5b-DNA-construct significantly inhibited the production of specific IgE and IgG1 antibodies and prevented the development of a lung pathology associated with inflammation. Thus, immunoprophylaxis with an expression vector containing the Phl p 5b sequence totally prevented the emergence of characteristics associated with type I allergy and chronic bronchitis.
Asunto(s)
Alérgenos/inmunología , Enfermedades Bronquiales/prevención & control , Inmunización , Inmunoterapia/métodos , Proteínas de Plantas/administración & dosificación , Vacunas de ADN/administración & dosificación , Alérgenos/administración & dosificación , Animales , Enfermedades Bronquiales/inmunología , Ratones , Ratones Endogámicos BALB C , Proteínas de Plantas/inmunología , Polen/inmunologíaRESUMEN
The therapeutic uses of hive-derived products by local people in four zones from the central part of Burkina Faso are described. Of 13 apitherapeutic applications recorded, only honey (12) and honeybee larvae (1) were used. The uses described included treatment of various gastrointestinal disorders, respiratory ailments, fatigue, vertigo, ophthalmic disorders, toothache, measles, wounds, burns, chest pains, period pains and postnatal disorders, male impotence as well as its application as a skin cleansing agent. The effectiveness against some of these conditions, e.g. measles, period pains and postnatal disorders, requires further investigation and confirmation.
Asunto(s)
Abejas , Miel , Animales , Enfermedades Bronquiales/tratamiento farmacológico , Burkina Faso , Evaluación Preclínica de Medicamentos/métodos , Dismenorrea/tratamiento farmacológico , Femenino , Enfermedades Gastrointestinales/tratamiento farmacológico , Humanos , Larva , Vigilancia de la Población/métodosRESUMEN
Tracheomalacia and bronchomalacia are becoming increasingly well recognized. Although pathologically benign conditions, they are responsible for considerable morbidity, occasional mortality and significant difficulties in the operating theatre and intensive care unit. We performed an extensive literature search to identify causal associations, methods of clinical and investigative assessment, treatment modalities and anaesthetic experience with these conditions.
Asunto(s)
Enfermedades Bronquiales , Anestesia General , Anestesia Local , Enfermedades Bronquiales/diagnóstico , Enfermedades Bronquiales/fisiopatología , Enfermedades Bronquiales/cirugía , Broncoscopía , Niño , Preescolar , Humanos , Lactante , Espirometría , Tomografía Computarizada por Rayos X , Enfermedades de la Tráquea/diagnóstico , Enfermedades de la Tráquea/fisiopatología , Enfermedades de la Tráquea/cirugíaRESUMEN
BACKGROUND AND OBJECTIVES: Photosan, a mixture of porphyrin oligomers as sensitizer for photodynamic therapy (PDT), carry the risk of prolonged photosensitivity of the skin. New sensitizer such as 5-aminolaevulinic acid (ALA) with low rates of skin phototoxicity appear to be promising alternatives. The aim of this study was to evaluate the efficacy of ALA compared to Photosan for PDT in malignant tracheo-bronchial stenosis. Reduction of tumor stenosis, increase in quality of life, and phototoxicity were considered as primary objectives. Improvement in clinical symptoms due to reduction of tumor stenosis, for example hemotysis, dyspnea, and poststenotic pneumonia were considered as secondary objectives. PATIENTS AND METHODS: After diagnostic work-up, photosensitization was done in 16 patients with ALA (60 mg/kg BW, oral, 6-8 hours prior to PDT) and in 24 patients with Photosan (2 mg/kg BW, i.v., 48 hours before PDT). The light dose was calculated as 100 J/cm(2) tumor length. Light at 630 nm was applied using a pumped dye laser. In both groups, additional hyperbaric oxygenation was applied at a level of 2 absolute atmospheric pressure. RESULTS: Stenosis diameter and Karnofsky performance status showed a significant improvement in favor of the Photosan-group, P = 0.00073 and 0.00015, respectively. In both groups no sunburn occurred due to phototoxicity of the sensitizer. CONCLUSION: Despite the limitations of a non-randomized study, photosensitization with Photosan seems to be more effective in PDT of malignant tracheo-bronchial stenosis compared to ALA.
Asunto(s)
Ácido Aminolevulínico/uso terapéutico , Enfermedades Bronquiales/tratamiento farmacológico , Neoplasias Pulmonares/complicaciones , Fotoquimioterapia , Fármacos Fotosensibilizantes/uso terapéutico , Porfirinas/uso terapéutico , Estenosis Traqueal/tratamiento farmacológico , Adenocarcinoma/complicaciones , Anciano , Ácido Aminolevulínico/efectos adversos , Enfermedades Bronquiales/etiología , Carcinoma de Células Escamosas/complicaciones , Constricción Patológica/tratamiento farmacológico , Constricción Patológica/etiología , Disnea/etiología , Femenino , Hematoporfirinas , Humanos , Oxigenoterapia Hiperbárica , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Cuidados Paliativos , Fármacos Fotosensibilizantes/efectos adversos , Proyectos Piloto , Porfirinas/efectos adversos , Estudios Prospectivos , Tasa de Supervivencia , Estenosis Traqueal/etiologíaRESUMEN
OBJECTIVE: The purpose of this study was to evaluate the potential utility of implantation of a nickel-titanium alloy (nitinol) stent for the treatment of malignant or benign tracheobronchial stenosis. METHODS: We evaluated 18 patients (14 men and 4 women) who received 24 nitinol stents, between November 1997 and May 2000. All 18 patients had severe dyspnea caused by tracheobronchial stenosis. The underlying condition was malignant disease in 15 patients, and benign tracheal collapse in the other 3 patients. RESULTS: Implantation of the stent was successfully performed in all patients. Seventeen patients experienced immediate clinical improvement in respiratory symptoms. The remaining 1 patient with a bronchial fistule after lobectomy did not benefit, and died of pneumonia at 16 days after the implantation. In 15 patients, the procedure was performed using a flexible bronchoscope under local anesthesia alone, while the remaining 3 patients needed intravenous sedation. There was no complication resulting from the stent implantation. Among the 3 patients with benign tracheal collapse, 2 patients were alive at 746 and at 401 days after the stent implantation, at the time of this report. One patient with cicatricial stenosis after intubation died of heart failure due to previous myocardial infarction. Among the 15 patients with malignant disease, 4 patients have survived for 177 to 305 days to date, while the other 11 patients have died of primary malignancy with a mean survival duration of 60.2 days. CONCLUSION: The nitinol stent was effective in treating malignant or benign tracheobronchial stenosis, and had some remarkable advantages compared with other tracheobronchial stents. In stenting, most procedures can be performed using flexible bronchoscope under local anesthesia.
Asunto(s)
Aleaciones/uso terapéutico , Enfermedades Bronquiales/terapia , Stents , Estenosis Traqueal/terapia , Adulto , Anciano , Anciano de 80 o más Años , Anestesia Local , Broncoscopía , Constricción Patológica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Tráquea/complicacionesRESUMEN
OBJECTIVES: Photodynamic tumor therapy (PDT) is based upon a photochemical reaction that is limited by the availability of molecular oxygen in the target tissue. The use of hyperbaric oxygenation (HBO) increases the amount of oxygen available for the process may thereby enhance the efficacy of PDT. We proved in a prospective, non-randomized clinical pilot study the acute effects on malignant bronchial stenosis and the technical feasibility of combined PDT/HBO. METHODS: Forty patients (29 males, 11 females, mean age: 64.3 years; range 39-82 years) with inoperable, advanced malignant bronchial tumor stenosis were studied prospectively. Photosensitization was carried out using a hematoporphyrin-derivative 2 mg/kg bw 48 h prior to PDT. The light dose was calculated as 300 J/cm fiber tip. The assessment of outcome 1 and 4 weeks after PDT/HBO was done by endoscopy, chest X-ray, spirometry, laboratory parameters, subjective report of dyspnea and Karnofsky performance status. RESULTS: At 1 and 4 weeks after the treatment the patients felt a significant improvement of dyspnea and hemoptysis alongside with an objective subsiding of poststenotic pneumonia, though spirometric parameters revealed no significant difference. A significant reduction of tumor stenosis (P<0.05) and an improvement of the Karnofsky performance status (P<0.05) were documented 1 and 4 weeks after PDT/HBO. No therapy related complications were observed. CONCLUSION: Although the small number of patients does not allow to draw definitive conclusions, the results suggest that combined PDT/HBO represents a new, safe and technically feasible approach. It enables efficient and rapid reduction of the endoluminal tumor load and helps conditioning the patient for further treatment procedures.